PHARMESIS INTERNATIONAL LTD. (BFK) $0.2

Year Ex Date Particulars
2015 2015-08-27 SHARE CONSOL OFFER OF 1 FOR 10
Pharmesis International Ltd., an investment holding company, develops, manufactures, and sells western medicines, and traditional Chinese medicines (TCM) in the People’s Republic of China. It operates through three segments: Western Drugs, TCM Formulated Drugs, and Distribution. The company’s pharmaceutical products include prescribed products and over-the-counter drugs. It offers pharmaceutical products in the form of tablets, granules, pills, etc. The company offers Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Gansu for use in treating acute and chronic hepatitis; Er Ding Granules for the treatment of jaundice, as well as clears heat toxin; and Xiao Shi Jian Pi for use in treating flatus, inappetency, dyspepsy, and spleen weakness. It also provides ShuLingHou tablets used in the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness; Lianpu Shuangqing for use in treating acute inflammation, such as dysentery and intestinal infection; Xiaoluotong Jiaonang for the treatment of rheumatoid arthritis and other rheumatic diseases; and Afenka for use in treating of migraine, relieves pain from headache, cold, nasosinusitis, muscle pain, menstrual pain, toothache, and arthritis. The company markets its western drugs under the Kinna brand name; and TCM formulated drugs under the Longlife brand name to hospitals. In addition, it engages in the wholesale of chemical drugs, biological raw products, TCM products, antibiotics, and antibiotics agents. Pharmesis International Ltd. was founded in 1996 and is headquartered in Chengdu, the People’s Republic of China.

© 2018 Dividends.sg